
|Articles|November 19, 2013
- Immunotherapy (Issue 1)
- Volume 1
- Issue 1
The Outlook for Immunotherapies
Author(s)Julie R. Brahmer, MD
Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses the outlook for immunotherapies in cancer care.
Advertisement
Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses the outlook for immunotherapies in cancer care.
Learn more aboutimmunotherapies in cancer
Articles in this issue
about 12 years ago
MPDL3280A Induces Durable Responses in NSCLC, Other Cancersabout 12 years ago
Immunotherapy—An Increasingly Important Role in Oncologyabout 12 years ago
Suzanne Topalian, MD, on PD-1 Targeted Therapyabout 12 years ago
Understanding Immunotherapy in Cancer: A Q&A with Antoni Ribas, MD, PhDabout 12 years ago
PD-1 and PD-L1 Antibodies in Lung Cancerabout 12 years ago
Checkpoint Inhibitors in Cancer Careabout 12 years ago
Search for Predictive Biomarkers of PD-1 Pathway Blockadeabout 12 years ago
Nivolumab Plus Ipilimumab in Advanced MelanomaAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
Gut Health & Myeloma: How Bacteria May Predict Transplant Success With Pooja Phull, MD
5










































